paracetamol teva 1000 mg tabletti
teva b.v. - paracetamol - tabletti - 1000 mg - parasetamoli
paracetamol teva 500 mg tabletti, kalvopäällysteinen
teva b.v. - paracetamol - tabletti, kalvopäällysteinen - 500 mg - parasetamoli
inzolfi 0.5 mg kapseli, kova
sandoz a/s - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
golpimec 0.5 mg kapseli, kova
neuraxpharm sweden ab - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
gaxenim 0.5 mg kapseli, kova
bausch health ireland limited - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
fingolimod tillomed 0.5 mg kapseli, kova
tillomed pharma gmbh - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod krka 0.5 mg kapseli, kova
krka, d.d., novo mesto - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - syöpälääkkeet - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.